3 - OSR Holdings, Inc. (0001840425) (Issuer)

BELLEVUE, Wash., Oct. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (NASDAQ:OSRH) today announced that on September 5, 2025, it received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The notice does not affect the listing of OSR Holdings' common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." In accordance with Nasdaq rules, the Company has until Marc

BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a  global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH

BELLEVUE, Wash., July 31, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical innovation approaches to health and wellness to support global health outcomes, today provided a transparency update regarding its Equity Line of Credit (ELOC) agreement with White Lion GBM Innovation Fund and related convertible instruments. Highlights: Total shares issued to date under structured financing: 2,308,382Commitment Shares: 519,481Convertible Notes: 745,193Warrant Exercises: 276,208Under the ELOC agreement:Registered Share Capacity: 9,5

BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical and wellness innovation, today issued a strategic update regarding its recently announced Term Sheet with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company pioneering noninvasive glucose monitoring technology. The transaction, once completed, will result in WORIO becoming a wholly owned subsidiary of OSR Holdings Co., Ltd. ("OSRK"), a Korean affiliate of OSRH. As previously disclosed, WORIO shareholders will

BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical device company developing next-generation noninvasive glucose monitoring technology. The agreement sets forth certain key terms for a strategic acquisition of WORIO by OSR Holdings' Korean affiliate, OSR Holdings Co., Ltd. ("OSRK"). Under the proposed structure, WORIO will become a wholly

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

BELLEVUE, Wash. and ZUG, Switzerland, July 9, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap

BELLEVUE, Wash. and ZUG, Switzerland, July 8, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced the official roadmap for a targeted $50 million security token offering (STO) planned for launch in the second half of 2025 under Regulation D of the U.S. Securities Act. The token, with the working title OSRT, will be a securitized digital asset representing OSR Holdings' equity exposure and is designed to align with the company's blockchain-based capital strategy. As part of this roadmap

SEOUL, South Korea and ZUG, Switzerland, May 22, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a public company dedicated to advancing innovation in healthcare and wellness, announced today that it has entered into a Memorandum of Understanding (MOU) with BCM Europe AG, its major shareholder, and Taekwondo Cooperative (TKD Coop), a global Taekwondo community organization, to explore the joint development of a security token, provisionally named the "OSRH Token". The initiative aims to enhance access to crypto-based liquidity and provide a basis for OSRH to launch crypto treasury strategies.

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

DEF 14A - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

PRE 14A - OSR Holdings, Inc. (0001840425) (Filer)

10-Q - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

8-K - OSR Holdings, Inc. (0001840425) (Filer)

BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions a